golfyeti - My impression is that the pricing for apabetalone is correct as it is not designed as an orphan drug to be used only on a limited number of patients. The drug referred to in the article you mentioned is for a rare disease  which suggests a limited potential user group.  Apabetalone's  potential market of 18.6 million patients is quite substantial and provides plenty of opportunity for our aquirer by just play with market share numbers.

By using a market penetration number of 50% and $5,000 per year drug cost you can still justify a share price of $200+ per share. I'm okay with that...are you? That's a little out there for a $2 stock today but the numbers can justify it.

All IMO, DYODD

tada